Live attenuated
A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
1. A triple mutated Bordetella strain which is a BPZE1 strain deposited with the Collection Nationale de Culture Microorganismes (C.N.C.M.) on Mar. 9, 2006, under number 1-3585.
2. An immunogenic composition comprising the attenuated mutated Bordetella strain according to claim 1 .
3. The immunogenic composition according to claim 2 , further comprising a pharmaceutically suitable excipient, vehicle and/or carrier.
4. The immunogenic composition according to claim 3 , further comprising an adjuvant.
5. A vaccine comprising the attenuated mutated Bordetella strain of claim 1 .
6. The vaccine according to claim 5 , formulated for intranasal administration.
7. A kit comprising the vaccine according to claim 5 and an information leaflet.
8. A vaccine comprising a live, attenuated mutated Bordetella pertussis strain comprising at least a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene which replaces the Bordetella ampG gene, and a pharmaceutically suitable excipient, vehicle and/or carrier, wherein the strain is able to colonize and induce protective immunity in a subject.
9. The vaccine according to claim 8 , wherein said Bordetella strain expresses less than 5% residual tracheal cytotoxin (TCT) activity.